3/20
05:29 pm
otlk
Outlook Therapeutics files to sell 21.72M shares of common stock for holders [Seeking Alpha]
Low
Report
Outlook Therapeutics files to sell 21.72M shares of common stock for holders [Seeking Alpha]
2/28
10:53 am
otlk
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration [Yahoo! Finance]
Low
Report
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration [Yahoo! Finance]
2/28
08:05 am
otlk
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
Medium
Report
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
2/24
08:16 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target lowered by analysts at Ascendiant Capital Markets from $33.00 to $24.00. They now have a "buy" rating on the stock.
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target lowered by analysts at Ascendiant Capital Markets from $33.00 to $24.00. They now have a "buy" rating on the stock.
2/19
09:00 am
otlk
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Medium
Report
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
2/18
08:00 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "neutral" rating re-affirmed by analysts at Chardan Capital. They now have a $3.00 price target on the stock.
Medium
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "neutral" rating re-affirmed by analysts at Chardan Capital. They now have a $3.00 price target on the stock.
2/18
08:00 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target lowered by analysts at HC Wainwright from $30.00 to $3.00. They now have a "buy" rating on the stock.
Medium
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target lowered by analysts at HC Wainwright from $30.00 to $3.00. They now have a "buy" rating on the stock.
2/14
09:35 am
otlk
https://seekingalpha.com/news/4408572-outlook-therapeutics-reports-q1-results [Seeking Alpha]
Low
Report
https://seekingalpha.com/news/4408572-outlook-therapeutics-reports-q1-results [Seeking Alpha]
2/14
08:20 am
otlk
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update [Yahoo! Finance]
Low
Report
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update [Yahoo! Finance]
2/14
08:05 am
otlk
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
Medium
Report
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
2/4
09:51 am
otlk
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment [Yahoo! Finance]
Medium
Report
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment [Yahoo! Finance]
2/4
09:05 am
otlk
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
Low
Report
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
1/31
08:12 am
otlk
Outlook Therapeutics names Faisal Sukhtian as chair [Seeking Alpha]
Low
Report
Outlook Therapeutics names Faisal Sukhtian as chair [Seeking Alpha]
1/31
08:05 am
otlk
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
Low
Report
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
1/23
09:05 am
otlk
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
Low
Report
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
1/22
11:57 am
otlk
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar [Yahoo! Finance]
Medium
Report
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar [Yahoo! Finance]
1/22
09:05 am
otlk
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
Medium
Report
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
1/17
09:17 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $12.00 price target on the stock.
Medium
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $12.00 price target on the stock.
1/17
07:56 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Medium
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
1/16
06:00 am
otlk
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
Low
Report
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
1/8
09:15 am
otlk
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
Medium
Report
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment